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Zika virus is a mosquito-borne ﬂavivirus with signiﬁcant public health concern
due to its association with neurological symptoms and intrauterine malformations.
Although it is endemic in tropical and subtropical areas, sexual transmission raises the
possibility of autochthonous spreading elsewhere. We describe the ﬁrst laboratory
diagnosed imported Zika-infections of Hungary, to highlight the challenges of
microbiological identiﬁcation of the pathogen, caused by serological cross-reactivity
and short viremia. Serological examination was carried out using indirect
immunoﬂuorescent assay and enzyme-linked immunosorbent assay. Plaque-reduction
neutralization test was used for veriﬁcation purposes. A wide range of clinical
specimens: serum, whole-blood, urine, saliva, and semen were analyzed by molecular
methods, and sequencing was applied in case of PCR positive results to identify the
virus strain. Zika-infected patients with previous vaccination against ﬂaviviruses or
possible ﬂavivirus infection in the past showed high serological cross-reactivity, and
even cross-neutralizing antibodies were observed. Zika virus RNA could be detected
in urine specimen in case of two patients, and in EDTA-anticoagulated whole-blood
sample of one patient. The detected strains belong to the Asian lineage of the virus. We
presume that serological investigation of imported Zika virus could be altered by
infections, vaccination of endemic ﬂaviviruses in Hungary and vice versa.
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Introduction
Zika virus (ZIKV) is a mosquito-borne ﬂavivirus, which, since its ﬁrst
isolation in 1947 in Uganda, has become a signiﬁcant public health concern due to
its rapid spread to new geographical areas, and it is associated with severe
neurological symptoms and intrauterine malformations [1–3]. ZIKV is also
capable of spreading vertically and sexually [4]; therefore, an imported infection
can be passed on to others even in areas, where its vector is not present. Thus, the
shedding of the virus in semen of infected men has been detected up to 370 days
after onset of symptoms [5]. Although most infections are asymptomatic, when it
is presented with only mild symptoms, such as low-grade fever, non-purulent
conjunctivitis, headache, rash, joint, and muscle pain [6], dengue virus (DENV)
and Chikungunya virus (CHIKV), which share the geographical distribution and
vectors of ZIKV [7], should also be considered as causative agents. As a member
of the genus Flavivirus, ZIKV is also characterized by serological cross-reactivity
and short viremia that makes its identiﬁcation challenging [8]. The primary vector
for ZIKV is Aedes aegypti, but other Aedes mosquitoes, such as Aedes albopictus
and Aedes africanus, could transmit the infection [9]. In Hungary, two Aedes
species are established: Aedes japonicus [10] and Aedes koreicus [11].
A. japonicus had low potential to transmit ZIKV in recent laboratory
experiments [12]. The potential of CHIKV transmission has been associated with
A. koreicus [13], but, to date, no evidence of ZIKV-transmission has been
described in the literature. Although the established Aedesmosquitoes of Hungary
do not play a role in spreading ZIKV, vertical and sexual transmission of imported
cases might occur; therefore, high vigilance and early detection of such infections
are important. Considering the latest vector surveillance results, A. albopictus was
introduced [14] in the southern region of the country, which raises the possibility
of autochthonous transmission in the future. Moreover, in many Mediterranean
countries of Europe A. albopictus, a potential vector for ZIKV, DENV, and
CHIKV is established [14] and A. aegypti is also present in some areas,
e.g., Madeira [15]. Other ﬂaviviruses associated with human infections are
endemic in Hungary: West Nile virus (WNV) [16], tick-borne encephalitis virus
(TBEV) [17], and Usutu virus (USUV) [18]. Human cases of WNV and TBEV
with diverse clinical symptoms occur annually [16, 17], while the ﬁrst human
USUV infection in Hungary was laboratory-conﬁrmed during the 2018 transmis-
sion season [19]. Moreover, part of the population is immunized against
TBEV [20], and vaccination against yellow fever virus (YFV) is also available
related to travel. Considering these possibilities, during the diagnosis of ZIKV
infections, serological analysis of other ﬂaviviruses is important to exclude
false-positive results caused by cross-reactions. Until recently, molecular
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techniques were considered to be second-line diagnostic methods for ﬂavivirus
infections due to the short viremia [21]. Recent studies describe that other clinical
materials such as urine and whole-blood could be used more efﬁciently for nucleic
acid testing because of longer virus shedding [22, 23].
In accordance with the European Union’s case deﬁnition manual for
laboratory conﬁrmation of acute ZIKV infections [24], at least one of the
following criteria must be met:
– Isolation of ZIKV from clinical specimen
– Detection of ZIKV nucleic acid or antigen in clinical specimen
– Detection of ZIKV-speciﬁc IgM antibodies in serum sample(s) and conﬁr-
mation by neutralization test
– Seroconversion or fourfold increase in the titer of Zika-speciﬁc antibodies in
paired sera
The aim of this study was to describe the detection of the ﬁrst laboratory-
conﬁrmed imported ZIKV-infections in Hungary and the differential diagnostic
challenges of serological and molecular methods used to exclude other possible
imported or endemic ﬂavivirus infections in the country. In this publication, we
describe the serological and molecular results of seven ZIKV-infected patients
with different ﬂavivirus-speciﬁc serological backgrounds.
Materials and Methods
Patients
During the 2016–2018 period, we tested samples of 603 patients (both
symptomatic and asymptomatic) for ZIKV (Figure 1). Altogether seven patients
had positive serological or molecular results for ZIKV, which are described in
this study; in all other cases, ZIKV infection could be excluded. Every patient
involved in the work traveled to areas affected with ZIKV circulation, prior to
sample collection. Some patients visited different endemic regions earlier. All
travelers conﬁrmed mosquito bites as mode of transmission; other possible
routes of infection (e.g., transfusion, transplantation, and sexual contact) could
be excluded. Six out of seven persons experienced at least one ZIKV-speciﬁc
symptom (rash or arthralgia or non-purulent conjunctivitis), four of them
reported additional characteristic symptoms. One patient developed no
symptoms at all. Two persons received vaccination against a ﬂavivirus (YFV
or TBEV) that may affect interpretation of the serological results due to possible
cross-reactivity. Table I summarizes most important anamnestic data of investi-
gated patients.
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Serological investigation
During serological investigation, ﬁrst-line diagnostic methods for detection
of ﬂavivirus-speciﬁc antibodies were in-house immunoﬂuorescence assay (IFA)
and commercial enzyme-linked immunosorbent assay (ELISA) kit (Euroimmun
Medizinische Labordiagnostika, Lübeck). In-house indirect IFA was carried out as
described previously in the literature [25], with minor modiﬁcation. Commercial
ELISA test (Euroimmun Medizinische Labordiagnostika) was performed accord-
ing to the manufacturer’s instructions.
ZIKV-speciﬁc immune response was investigated in patient sera using an
IFA together with ELISA kit for the detection of ZIKV-speciﬁc IgG and IgM
antibodies. For veriﬁcation, following the guidelines of Center for Disease
Prevention and Control [26], the presence of neutralizing antibodies for both
ZIKV and DENVwas tested. We used an in-house plaque-reduction neutralization
assay (PRNT), following the instructions of World Health Organization [27] with
minor modiﬁcation. As serological cross-reactivity is well known among the
Flavivirus genus [8], sera were also tested for its other members: DENV – due to
the shared endemic region, vectors, and symptoms with ZIKV [7], WNV, and
TBEV as they are endemic in Hungary [16, 17, 28]; therefore, a possible previous
infection had to be excluded. DENV-speciﬁc IgG and IgM antibodies were tested
by both IFA and ELISA kit. For testing of DENV NS1 antigen, a commercial
ELISA kit (Euroimmun Medizinische Labordiagnostika) was applied following
the manufacturer’s instructions, in case of serum specimens collected 9 days or
earlier after symptom onset, based on the estimated duration time of NS1 antigen
circulation in sera [29]. We used IFA to detect TBEV- and WNV-speciﬁc IgG
Figure 1. Distribution of the 603 cases tested for ZIKV infection between 2016 and 2018 regarding
symptoms. A majority of the patients tested were symptomless and requested screening after
traveling to endemic areas
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antibodies. As the ﬁrst human USUV infection in Hungary was diagnosed in
2018 [19], samples collected this year were tested for USUV-speciﬁc IgG
antibodies by IFA. Considering the circulation of USUV virus in birds in the
country during the previous years [30], a retrospective analysis was also carried out
in samples collected in 2016 and 2017, if the remaining volumes were sufﬁcient.
Taking into account the patients’ travel and vaccination history, serological tests for
other members of the genus Flavivirus, such as YFV, were also performed by IFA
method. A possible coinfection with CHIKV, due to its shared endemic region,
vectors, and symptoms with ZIKV [7], was also investigated serologically in case of
every patient using commercial ELISA kit (Euroimmun Medizinische Labordiag-
nostika) according to the manufacturer’s instructions.
Molecular investigation
For ZIKV RNA detection from human urine, serum, whole-blood, saliva,
throat swab, and semen samples, total nucleic acid was extracted from 140 μl of
the specimens using a QIAamp Viral RNAMini Kit (QIAGEN, Hilden) according
to the manufacturer’s instructions. Following a reverse-transcription step,
TaqMan assay was carried out for ZIKV and DENV, respectively. The real-time
RT-PCR assay for ZIKV was performed as published earlier with minor
modiﬁcations [31].
In case of those patients, where elevated antibody levels were detected for
both ZIKV and DENV, and time and conditions of sample collection were suitable
for molecular analysis, a serotype-speciﬁc multiplex real-time RT-PCR assay was
performed as published earlier [32] to exclude a possible dengue infection or
coinfection.
Viral RNA from ZIKV-speciﬁc real-time RT-PCR-positive samples was also
ampliﬁed using an in-house nested RT-PCR protocol with primer sets speciﬁc for
the 269 nt sequence of the NS3 and NS4A overlapping region of the viral genome
(primer sequences are the following: ﬁrst-round forward primer: CTGGCTTGAAG-
CAAGAATGC; ﬁrst-round reverse primer: GGTCTCTAGGGTCTCCGGCA;
second-round forward primer: CCTATCAGGTTGCATCTGCC; second-round
reverse primer: AAGGCCTGCTTCCAGTCTCT). For preparation for Sanger
sequencing, nested PCR amplicons were extracted using a PCR AdvancedTM PCR
Clean Up System (Viogen Biotek Corporation, New Taipei City, Taiwan, Republic
of China) following the manufacturer’s instructions. Direct sequencing of the
amplicons was performed on 3500 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA) using BigDye® terminator V3.1 cycle sequencing kit
(Applied Biosystems), according to the manufacturer’s recommendations.
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Nucleotide sequences were identiﬁed using Basic Local Alignment Search Tool
(BLAST; http://blast.ncbi.nlm.nih.gov/Blast.cgi). Phylogenetic neighbor-joining
tree was created by Molecular Evolutionary Genetic Analysis (MEGA) 5.05
software, using ClustalW alignments of partial segment of the NS3 and NS4A
overlapping region. One thousand replicates for bootstrap testing were generated.
The evolutionary distance was calculated using the Kimura 2-parameter model
Virus isolation
To attempt virus isolation, samples were ﬁltered on 0.22 microﬁlter to
remove any potential bacterial or fungal agents, then inoculated onto Vero cells
approximately 85%–90% conﬂuent after at least 1 day after seeding. After
incubation for 7 days, Vero cells were harvested, and detection of viral particles
was attempted by the aforementioned molecular methods.
Results
In 2016, 5 out of 196 patients had positive serological or molecular results of
ZIKV. Four of them had Zika-speciﬁc symptoms and one was symptomless. In
2017, altogether 219 persons’ samples were tested, and 1 symptomatic patient
with ZIKV infection could be diagnosed. In 2018, one case with ZIKV-speciﬁc
symptoms could be conﬁrmed out of the 188 tested.
Summarizing, among the 603 patients tested between 2016 and 2018, 7
patients showed reactive serological results for ZIKV (Table II). No patients had
antibodies against CHIKV. ELISA seemed less cross-reactive compared to IFA. In
case of Patients 2, 3, and 5, serological response to a probable previous TBEV or
WNV infection could be detected (Table III), but it might be a result of
cross-reactivity as well. Patients 2 and 6 had history of vaccination against YFV
or TBEV infection, and previous infection with other ﬂavivirus could not be
excluded according to the measured antibody levels (Table III). Although PRNT is
the recommended serological method for conﬁrmation [24], it proved to be
challenging in case of secondary ﬂavivirus infections or ﬂavivirus infections
following previous vaccination.
Patient 1
All sera of Patient 1 tested positive for ZIKV-speciﬁc IgM and IgG
antibodies (Table II) and no signiﬁcant cross-reactivity with other ﬂaviviruses
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were observed (Tables II and III). PRNT assay was carried out for veriﬁcation and
revealed high-neutralizing titer for ZIKV (Table II). No ZIKV RNA could be
detected from clinical specimens of the patient (Table IV), as remarkable time
passed between onset of symptoms and sample collection.
Patient 2
With history of previous YFV vaccinations and a possible former Zika or
dengue infection, Patient 2 has elevated level of neutralizing antibodies for both
ZIKV and DENV (Table II). Even though a fourfold titer difference could be
observed between the results of ZIKV and DENV PRNT, considering the complex
serological results, including the presence of anti-ZIKV IgM antibodies in the ﬁrst
serum of the patient, the possibility of an acute DENV infection after a previous ZIKV
infection could not be excluded as the original antigenic sin phenomenon may lead to
increased antibody titers of the previous infection [33, 34]. Moreover, previous
infection with other ﬂavivirus could not be excluded either according to the measured
antibody levels (Table III), but it might be a result of serological cross-reactivity.
Patient 3
Neutralizing antibody titers for ZIKV and DENV are also elevated in case of
Patient 3 (Table II), who reported no previous ﬂavivirus vaccination, but
Table IV. ZIKV-speciﬁc real-time RT-PCR results of Patients 1, 2, 6, and 7 regarding the days after
symptom onset
Patient Sample ZIKV qPCR
Patient 1 Serum 1 (56 days), serum 2 (61 days) Negative
Urine 1 (56 days), urine 2 (61 days) Negative
Saliva (61 days), throat swab (61 days) Negative
Semen 1 (63 days), semen 2 (71 days), semen 3 (78 days) Negative
Patient 2 Serum 1 (2014), serum 2 (2016) Negative
Urine (2016) Negative
Patient 6 Serum 1 (3 days), serum 2 (14 days) Negative
Urine 1 (3 days) Positive
Urine 2 (14 days) Negative
Saliva (14 days), throat swab (14 days) Negative
Patient 7 Serum (7 days) Negative
Whole blood (7 days) Positive
Urine (7 days) Positive
Whole blood (14 days) Negative
Note: Positive results are in bold to highlight the specimen types with detectable level of viral RNA. ZIKV:
Zika virus; qPCR: quantitative polymerase chain reaction.
432 NAGY ET AL.
Acta Microbiologica et Immunologica Hungarica 66, 2019
coinfection or earlier infection with DENV or ZIKV during prior travels to
endemic regions might have occurred. Moreover, IgM antibodies were not
detected in serum of Patient 3 neither for ZIKV, nor for DENV, which is a
common observation in case of secondary ﬂavivirus infections [35, 36].
TBEV- and WNV-speciﬁc IgG antibodies were detected by indirect
hemagglutination (IH) IFA in all sera of the patient (Table III) that may refer
to cross-reaction or previous infection. Even the role of TBEV vaccination early in
childhood could not be ruled out, as the patient had no information on his
childhood vaccinations.
Patient 4
Serum collected 9 months after symptom onset was tested positive for
ZIKV-speciﬁc IgG antibodies and was conﬁrmed by PRNT. No ZIKV-speciﬁc
IgM antibodies could be detected. Although serum investigated by IH IFA
and ELISA methods also proved to be positive for DENV-speciﬁc IgG
antibodies, it was considered a result of cross-reactivity, as DENV PRNT
assay excluded a former DENV infection (Table II). Cross-reactivity with
endemic ﬂaviviruses of Hungary was not observed during the serological
analysis (Table III).
Patient 5
Serum of Patient 5 was tested positive for ZIKV-speciﬁc IgG antibodies
and was conﬁrmed by PRNT. No ZIKV-speciﬁc IgM antibodies could be
detected. Same as in case of Patient 4, serum investigated by IH IFA and ELISA
methods also proved to be positive for DENV-speciﬁc IgG antibodies,
but it was considered a result of cross-reactivity, as DENV PRNT assay
excluded a former DENV infection (Table II). Cross-reactivity with endemic
ﬂaviviruses of Hungary was not observed during the serological analysis
(Table III).
Patient 6
Sera of Patient 6 were tested positive for ZIKV-speciﬁc IgM antibodies and
more than fourfold titer increase could be observed by serological analysis in sera
collected 2 weeks apart. All sera of the patient were tested positive for
DENV-speciﬁc IgG antibodies with fourfold titer difference in ﬁrst and second
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sera. No DENV-speciﬁc IgM antibodies could be detected in any of his sera.
PRNT testing of third serum of the patient also gave controversial results: ZIKV
and DENV neutralizing antibodies could be detected in different titers (Table II).
As the patient received TBEV vaccination and reported recent travels to DENV
endemic regions, both cross-reaction or a previous DENV infection could
explain the reactive results. Although Patient 6 has history of vaccination
against TBEV, previous infection with other endemic ﬂavivirus of Hungary
could not be excluded either according to the measured antibody levels
(Table III).
Patient 6 has detectable level of ZIKV RNA in his ﬁrst urine sample. Second
urine sample collected 3 days later, along with sera, saliva, and throat swab
samples of the patient proved to be negative for ZIKV RNA using real-time RT-
PCR method (Table IV). PCR positive results were conﬁrmed using in-house
nested RT-PCR and Sanger sequencing. Phylogenetic analysis based on the NS3
and NS4 overlapping regions of the viral RNA obtained from sample of Patient 6
revealed close relationship with virus strains from Thailand and Singapore
(GenBank accession number: MG266396) (Figure 2). Virus isolation was
attempted using Vero cell lines, but no infectious virus particles were recovered.
Patient 7
First serum of Patient 7 was tested negative for ZIKV-speciﬁc IgG
antibodies by both IH IFA and ELISA methods. ELISA gave an indeterminate
result for ZIKV-speciﬁc IgM antibodies. During the analysis of the second and
third sera of the patient, seroconversion could be observed, as high levels of
IgG antibodies were detected and IgM tests also gave positive results. Cross-
reactive antibodies were detected from third serum specimen of the patient by
IFA as PRNT excluded DENV infection (Table II). A possible acute infection
of TBEV, WNV, and USUV could also be excluded based on the incubation
time, absence of IgM antibodies, and moderated IgG titers (Table III). In case of
Patient 7, ZIKV RNA could be detected in ﬁrst whole blood and urine
specimen, while ﬁrst serum and second whole blood were tested negative by
real-time RT PCR assay. (Table IV). PCR positive results were conﬁrmed using
in-house nested RT-PCR and Sanger sequencing. Phylogenetic analysis based
on the NS3 and NS4 overlapping regions of the viral RNA obtained from
samples of Patient 7 revealed close relationship with virus strains from Thai-
land and Singapore (GenBank accession number: MK434848) (Figure 2). Virus
isolation was attempted using Vero cell lines, but no infectious virus particles
were recovered.
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Discussion
Evaluation of serological and molecular results of the patients is discussed in
this section.
Considering the patients’ medical and travel history, symptoms, and the
available epidemiological data together with the microbiological results, acute ZIKV
infection could be conﬁrmed in case of Patients 1, 6, and 7. Previous ZIKV infection
was diagnosed in case of Patients 4 and 5. Based on the complex serological results
and anamnestic data of Patient 2, a previous DENV or ZIKV infection or coinfection
could be suspected during her stay in 2013–2014 in Bora Bora. Considering the
PRNT and IgM results of Patient 3, a recent ZIKV infection after a former DENV
infection or a recent DENV infection following a previous ZIKV is presumed.
Figure 2. Phylogenetic neighbor-joining tree of ZIKV strains detected in specimens of Patient 6
(GenBank: MG266396) and Patient 7 (GenBank: MK434848), marked by black dots. The
GenBank accession numbers, countries where it is identiﬁed and year of detection, are indicated in
the tree. Phylogenetic neighbor-joining tree was created by Molecular Evolutionary
Genetic Analysis (MEGA) 5.05 software, using ClustalW alignments of 269-nt-long partial
segment of the NS3 and NS4A overlapping region. One thousand replicates for bootstrap
testing were generated. The evolutionary distance was calculated using the Kimura
2-parameter model
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Previously described results help demonstrating the difﬁculties of serologi-
cal diagnosis of ZIKV infection as a secondary ﬂavivirus infection after either
other imported or endemic ﬂavivirus infections or vaccination. These challenges
seem to play an important role in laboratory diagnosis even in those regions, where
ZIKV is not circulating, but other ﬂaviviruses are present. Moreover, ﬁndings of
molecular analysis enhance the importance of proper timing of sample collection
for molecular testing, in correlation with the duration of virus nucleic acid
detection from different clinical specimens, which could explain the negative
results of PCR analysis of samples collected late after symptom onset.
In the event of multiple ﬂavivirus infections, serological results could be
altered by the cross-reactive antibodies of previous infections [35, 37]. In case of
ZIKV, this phenomenon is not unusual, as this pathogen shares its endemic region
with DENV, a ﬂavivirus with 54%–58% homologous nucleotide sequence in the
envelope protein coding region [38]. Recent studies demonstrated that in areas
where dengue is present, by the time of the emergence of ZIKV, most persons have
been exposed to at least one DENV serotype [39]. A majority of the screening
serological methods (ELISA and immunoﬂuorescence) are confounded by this
cross-reactivity. Moreover, sera collected early after DENV infection showed
cross-neutralizing effects for ZIKV and even cross-protection in animal models
was reported in the literature [37, 40–43]. Not DENV is the only important
ﬂavivirus to consider when it comes to serological analysis of a possible ZIKV
infection. YFV is reemerging in South America [44–46] and Africa [47–49], and a
great number of travelers are immunized with the live attenuated vaccine just few
weeks prior to the journey to endemic countries. In addition, a majority of the
European territories are affected by one or more ﬂaviviruses: TBEV, WNV, and
USUV [16, 17, 30]; thus, these infections are mainly asymptomatic or have
subclinical manifestation with no alarming symptoms [50, 51]. Given that IgM
antibodies not always reach the detectable level during a secondary or multiple
ﬂavivirus infection and IgG level elevates rapidly [52], high ﬂavivirus antibody
titers are present during symptom onset and diagnosis based on only serological
techniques could be challenging. Even the neutralization assays might lead to
controversial results, as cross-neutralizing antibodies might occur [37]. Another
characteristic phenomenon of the Flavivirus genus, the so-called original antigenic
sin, also complicates the serological diagnosis; it is marked by the failure of the
immune system to produce protective antibodies against a pathogen, which is
antigenically related to the strain of a previous infection or vaccination of the host
[33, 34]. Moreover, this failure could be responsible for antibody-dependent
enhancement (ADE) of infectivity, when cross-reactive but non-neutralizing
antibodies bind to the virus and mediate endocytosis via Fc receptors into dendritic
cells, macrophages, and monocytes, which lead to intracellular viral replication
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and higher viral load resulting in more severe symptoms [53, 54]. The described
cases of Patients 2 and 6 support this theory: both patients were previously
vaccinated by a ﬂavivirus; thus, exposition to previous DENV infection is also
possible considering the frequent travels to endemic areas. Their serological
results are complex and described by cross-reactivity and elevating IgG titers
for more than one ﬂavivirus; thus, both patients belong to the minority of the
population, who experience clinical symptoms during ﬂavivirus infection.
Until recently, the molecular methods for detection of ﬂavivirus infections
were considered second-lane techniques because of the short viremia [21].
Nowadays, numerous studies highlight the importance of molecular analysis, not
only to overcome the complications of the serological results, but also to monitor
the epidemics and the virus evolution of these important pathogens [22]. Similarly
to other ﬂaviviruses, like WNV, longer viral RNA detection was observed in urine
and whole-blood samples of ZIKV-infected patients [23, 55–58]. Additional
samples, such as saliva, semen, and cervical swab, can be used for viral RNA
detection for different time periods according to the literature [55]. Furthermore,
elongated viral RNA positivity of maternal serum refers to intrauterine ZIKV
infection, as viremia is maintained by the viral replication in the fetal tissues and
the placenta [59]. Molecular examination of the amniotic ﬂuid could be offered in
such cases to conﬁrm the diagnosis [60], especially when the serodiagnosis is
altered by the pregnancy or previous ﬂavivirus infection or vaccination.
Limitations of molecular tests include the timing of sample collection, special
conditions required for sample storage and transportation, and most importantly
the fact that intermittent shedding of viral RNA frequently occurs [61]; therefore,
repeated sample collection is desired.
In conclusion, during the serological analysis of a suspected ZIKV
infection of travelers living in non-tropical countries, the serological investi-
gation of endemic ﬂaviviruses and the vaccination history should be underlined,
because recent ﬂavivirus infections could complicate and even cause false-
positive serological results. Although the case deﬁnition for a conﬁrmed ZIKV
infection is met in the event of a fourfold titer increase or conﬁrmation of
serological results by neutralization assay, the interpreted cases demonstrate
that these criteria should be handled with caution if multiple ﬂavivirus
infections occur. On the contrary, cross-reactive antibodies of a previous
ZIKV infection raise the possibility of complicating the serodiagnosis of the
endemic ﬂavivirus infections of Hungary. Anti-TBEV and anti-WNV titers of
Patients 3 and 5 are elevated, although no know vaccination or previous
infection is reported. The question whether the observed antibody levels are
the results of a previous infection, despite the relatively moderate titers, or
caused by the cross-reactive antibodies of the acute infection, needs further
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examination. The presumption that an acute ZIKV infection may alter consid-
erably the serodiagnosis of the endemic Hungarian ﬂaviviruses is still unclear
and requires further investigation for the closer understanding of original
antigenic sin and ADE of infectivity, two characteristic phenomena of the
Flavivirus genus [33, 34, 54, 62].
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